tert-butyl 4-(5-amino-1,3,4-thiadiazol-2-yl)piperazine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-(5-amino-1,3,4-thiadiazol-2-yl)piperazine-1-carboxylate
• 英文别名: tert-Butyl 4-(5-amino-1,3,4-thiadiazol-2-yl)tetrahydro-1(2H)-pyrazinecarboxylate
• 化学式: C₁₁H₁₉N₅O₂S
• 分子量: 285.37
• InChiKey: UYCOBVUFFIQOFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  113
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(5-amino-1,3,4-thiadiazol-2-yl)piperazine-1-carboxylate 在 盐酸 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 10.0h， 生成 3-(2-cyanopropan-2-yl)-N-(5-(4-((2,5-dimethylphenyl)sulfonyl)piperazin-1-yl)-1,3,4-thiadiazol-2-yl)benzamide
  参考文献：
  名称：

  Synthesis of new 2,5-disubstituted-1,3,4-thiadiazole derivatives and their in vivo anticonvulsant activity

  摘要：

  A series of 2,5-disubstituted-1,3,4-thiadiazole derivatives were synthesized by the reaction of 3-(2-cyanopropan-2-yl)-N-(5-(piperazine-1-yl)-1,3,4-thiadiazol-2-yl)benzamide with various sulfonyl chlorides and evaluated for their anticonvulsant activity in MES test. Rotorod method was employed to determine the neurotoxicity. The purity of the compounds is confirmed on the basis of their elemental analysis. The structures of all the new compounds are established on the basis of 1H NMR and mass spectral data. Out of fifteen compounds, three were found to be potent anticolvunstants. The same compounds showed no neurotoxicity at the maximum dose administered (100 mg/kg).

  DOI：

  10.1134/s1068162014010051
• 作为产物：
  描述：

  2-氨基-5-溴-1,3,4-噻二唑 、 N-Boc-哌嗪 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以76%的产率得到tert-butyl 4-(5-amino-1,3,4-thiadiazol-2-yl)piperazine-1-carboxylate
  参考文献：
  名称：

  [EN] GLYCOSIDASE INHIBITORS
  [FR] INHIBITEURS DE GLYCOSIDASES

  摘要：

  式（I）中A、R、W、Q、n和m的含义如权利要求书所述，可用于治疗tau病和阿尔茨海默病。

  公开号：

  WO2017144639A1

文献信息

• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021123291A1

  公开（公告）日：2021-06-24

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病的用途，例如tau病变，特别是阿尔茨海默病或进行性上行性核瘫痪；以及伴有tau病理的神经退行性疾病，特别是由C9ORF72突变引起的肌萎缩侧索硬化或额颞叶痴呆；或α-突触核蛋白病，特别是帕金森病、帕金森病引起的痴呆（或由帕金森病引起的神经认知障碍）、带有Lewy小体的痴呆、多系统萎缩，或由高雪氏病引起的α-突触核蛋白病。
• [EN] ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES<br/>[FR] SELS D'ADDITION D'ACIDE DE DÉRIVÉS DE PIPÉRAZINE
  申请人：ASCENEURON S A

  公开号：WO2017144637A1

  公开（公告）日：2017-08-31

  The invention relates to acid addition salts of piperazine derivatives, as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and in particular as glycosidase inhibitors.

  该发明涉及哌嗪衍生物的酸加盐，以及其固体形式，如多型形式，这些形式可用作药用成分，特别是作为糖苷酶抑制剂。
• [EN] SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE LA PROTÉINE SHP2 PHOSPHATASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：RELAY THERAPEUTICS INC

  公开号：WO2019165073A1

  公开（公告）日：2019-08-29

  The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.

  本公开涉及新颖化合物及其药物组合物，以及利用本公开的化合物和组合物抑制SHP2磷酸酶活性的方法。本公开还涉及但不限于利用本公开的化合物和组合物治疗与SHP2失调相关的疾病的方法。
• [EN] 1,3,4-THIADIAZOL-2-YL-BENZAMIDE DERIVATIVES AS INHIBITORSOF THE WNT SIGNALLING PATHWAY<br/>[FR] DÉRIVÉS DE 1,3,4-THIADIAZOL-2-YL-BENZAMIDE UTILISÉS EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION WNT
  申请人：BAYER PHARMA AG

  公开号：WO2016131808A1

  公开（公告）日：2016-08-25

  The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及通用式（I）所述的Wnt信号通路抑制剂，以及制备该类化合物的方法，用于制备该类化合物的有用中间体化合物，包含该类化合物的药物组合物和组合物，以及利用该类化合物制造用于治疗或预防疾病的药物组合物，特别是治疗过度增生疾病的药物组合物，作为唯一药剂或与其他活性成分组合使用。
• 1,3,4-thiadiazoles useful for the treatment of CMV infections
  申请人：Pharmacia & Upjohn Company

  公开号：US06150385A1

  公开（公告）日：2000-11-21

  The present invention presents novel 1,3,4-thiadiazole derivatives of formula I ##STR1## which have useful antiviral activity against herpes virus, cytomegalovirus (CMV).

  本发明提供了新型的1,3,4-噻二唑衍生物，其化学式为I ##STR1## 这些衍生物对于疱疹病毒、巨细胞病毒（CMV）具有有用的抗病毒活性。